nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—L-DOPA—Melphalan—peripheral nervous system neoplasm	0.391	1	CrCrCtD
Mesalazine—MPO—Cisplatin—peripheral nervous system neoplasm	0.132	0.507	CbGbCtD
Mesalazine—PTGS2—Cisplatin—peripheral nervous system neoplasm	0.0454	0.175	CbGbCtD
Mesalazine—PTGS2—Etoposide—peripheral nervous system neoplasm	0.0446	0.172	CbGbCtD
Mesalazine—PTGS1—Etoposide—peripheral nervous system neoplasm	0.0377	0.145	CbGbCtD
Mesalazine—PPARG—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.00296	0.728	CbGdCrCtD
Mesalazine—PPARG—Teniposide—Etoposide—peripheral nervous system neoplasm	0.00111	0.273	CbGdCrCtD
Mesalazine—CHUK—Signaling by FGFR—NRAS—peripheral nervous system neoplasm	7.44e-05	0.000879	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Receptor Signaling Pathway—HRAS—peripheral nervous system neoplasm	7.44e-05	0.000879	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—NRAS—peripheral nervous system neoplasm	7.41e-05	0.000875	CbGpPWpGaD
Mesalazine—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—AKT1—peripheral nervous system neoplasm	7.37e-05	0.000871	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—AKT1—peripheral nervous system neoplasm	7.37e-05	0.000871	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—NRAS—peripheral nervous system neoplasm	7.37e-05	0.000871	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—MYC—peripheral nervous system neoplasm	7.33e-05	0.000867	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—COX2—peripheral nervous system neoplasm	7.27e-05	0.000858	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—NRAS—peripheral nervous system neoplasm	7.26e-05	0.000858	CbGpPWpGaD
Mesalazine—CHUK—B Cell Receptor Signaling Pathway—AKT1—peripheral nervous system neoplasm	7.25e-05	0.000856	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—PTPN11—peripheral nervous system neoplasm	7.25e-05	0.000856	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IFNB1—peripheral nervous system neoplasm	7.21e-05	0.000852	CbGpPWpGaD
Mesalazine—CHUK—PI-3K cascade—AKT1—peripheral nervous system neoplasm	7.19e-05	0.000849	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—PTPN11—peripheral nervous system neoplasm	7.12e-05	0.000842	CbGpPWpGaD
Mesalazine—CHUK—PI3K/AKT activation—AKT1—peripheral nervous system neoplasm	7.02e-05	0.000829	CbGpPWpGaD
Mesalazine—IKBKB—TCR Signaling Pathway—AKT1—peripheral nervous system neoplasm	6.98e-05	0.000824	CbGpPWpGaD
Mesalazine—CHUK—Toll-like Receptor Signaling Pathway—AKT1—peripheral nervous system neoplasm	6.96e-05	0.000823	CbGpPWpGaD
Mesalazine—CHUK—GAB1 signalosome—AKT1—peripheral nervous system neoplasm	6.96e-05	0.000823	CbGpPWpGaD
Mesalazine—PTGS2—C-MYB transcription factor network—MYC—peripheral nervous system neoplasm	6.95e-05	0.000821	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD34—peripheral nervous system neoplasm	6.94e-05	0.000821	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—NRAS—peripheral nervous system neoplasm	6.93e-05	0.000819	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—NRAS—peripheral nervous system neoplasm	6.93e-05	0.000819	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—NRAS—peripheral nervous system neoplasm	6.93e-05	0.000819	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—NRAS—peripheral nervous system neoplasm	6.87e-05	0.000812	CbGpPWpGaD
Mesalazine—IKBKB—TNF alpha Signaling Pathway—AKT1—peripheral nervous system neoplasm	6.86e-05	0.00081	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by Interleukins—HRAS—peripheral nervous system neoplasm	6.83e-05	0.000807	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—NRAS—peripheral nervous system neoplasm	6.81e-05	0.000805	CbGpPWpGaD
Mesalazine—CHUK—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—peripheral nervous system neoplasm	6.8e-05	0.000804	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—NRAS—peripheral nervous system neoplasm	6.78e-05	0.000801	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—CASP3—peripheral nervous system neoplasm	6.78e-05	0.000801	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PPP3R1—peripheral nervous system neoplasm	6.69e-05	0.00079	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—NRAS—peripheral nervous system neoplasm	6.59e-05	0.000778	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Receptor Signaling Pathway—AKT1—peripheral nervous system neoplasm	6.57e-05	0.000776	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—NRAS—peripheral nervous system neoplasm	6.56e-05	0.000775	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—BCHE—peripheral nervous system neoplasm	6.51e-05	0.000769	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—NRAS—peripheral nervous system neoplasm	6.42e-05	0.000758	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	6.34e-05	0.000749	CbGpPWpGaD
Mesalazine—Pneumonia—Epirubicin—peripheral nervous system neoplasm	6.32e-05	0.000242	CcSEcCtD
Mesalazine—IKBKB—Toll-like Receptor Signaling Pathway—AKT1—peripheral nervous system neoplasm	6.31e-05	0.000746	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD34—peripheral nervous system neoplasm	6.3e-05	0.000744	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—NRAS—peripheral nervous system neoplasm	6.29e-05	0.000743	CbGpPWpGaD
Mesalazine—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	6.29e-05	0.00024	CcSEcCtD
Mesalazine—Infestation—Epirubicin—peripheral nervous system neoplasm	6.29e-05	0.00024	CcSEcCtD
Mesalazine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	6.28e-05	0.00024	CcSEcCtD
Mesalazine—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	6.27e-05	0.00024	CcSEcCtD
Mesalazine—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	6.27e-05	0.00024	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	6.23e-05	0.000238	CcSEcCtD
Mesalazine—Rash—Dactinomycin—peripheral nervous system neoplasm	6.23e-05	0.000238	CcSEcCtD
Mesalazine—Decreased appetite—Etoposide—peripheral nervous system neoplasm	6.22e-05	0.000238	CcSEcCtD
Mesalazine—ALOX5—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.21e-05	0.000734	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	6.21e-05	0.000734	CbGpPWpGaD
Mesalazine—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	6.19e-05	0.000237	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—NTS—peripheral nervous system neoplasm	6.18e-05	0.00073	CbGpPWpGaD
Mesalazine—Renal failure—Epirubicin—peripheral nervous system neoplasm	6.18e-05	0.000236	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	6.17e-05	0.000236	CcSEcCtD
Mesalazine—CHUK—Disease—PPP3R1—peripheral nervous system neoplasm	6.17e-05	0.000729	CbGpPWpGaD
Mesalazine—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	6.17e-05	0.000236	CcSEcCtD
Mesalazine—Fatigue—Etoposide—peripheral nervous system neoplasm	6.17e-05	0.000236	CcSEcCtD
Mesalazine—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	6.16e-05	0.000236	CcSEcCtD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	6.14e-05	0.000726	CbGpPWpGaD
Mesalazine—Jaundice—Epirubicin—peripheral nervous system neoplasm	6.13e-05	0.000234	CcSEcCtD
Mesalazine—Stomatitis—Epirubicin—peripheral nervous system neoplasm	6.13e-05	0.000234	CcSEcCtD
Mesalazine—ALOX5—Metabolism—TH—peripheral nervous system neoplasm	6.12e-05	0.000723	CbGpPWpGaD
Mesalazine—Pain—Etoposide—peripheral nervous system neoplasm	6.12e-05	0.000234	CcSEcCtD
Mesalazine—Constipation—Etoposide—peripheral nervous system neoplasm	6.12e-05	0.000234	CcSEcCtD
Mesalazine—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	6.11e-05	0.000234	CcSEcCtD
Mesalazine—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	6.11e-05	0.000234	CcSEcCtD
Mesalazine—IKBKB—MAPK Signaling Pathway—MYC—peripheral nervous system neoplasm	6.11e-05	0.000722	CbGpPWpGaD
Mesalazine—Dysuria—Doxorubicin—peripheral nervous system neoplasm	6.1e-05	0.000233	CcSEcCtD
Mesalazine—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	6.1e-05	0.000233	CcSEcCtD
Mesalazine—CHUK—Signaling by SCF-KIT—HRAS—peripheral nervous system neoplasm	6.09e-05	0.000719	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	6.08e-05	0.000718	CbGpPWpGaD
Mesalazine—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	6.06e-05	0.000232	CcSEcCtD
Mesalazine—IKBKB—Immune System—PPP3R1—peripheral nervous system neoplasm	6.06e-05	0.000716	CbGpPWpGaD
Mesalazine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	6.06e-05	0.000232	CcSEcCtD
Mesalazine—PTGS2—Metabolism—HSD17B12—peripheral nervous system neoplasm	6.06e-05	0.000715	CbGpPWpGaD
Mesalazine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	6.04e-05	0.000231	CcSEcCtD
Mesalazine—Sweating—Epirubicin—peripheral nervous system neoplasm	6.03e-05	0.00023	CcSEcCtD
Mesalazine—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	6.03e-05	0.00023	CcSEcCtD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	6.02e-05	0.000712	CbGpPWpGaD
Mesalazine—Haematuria—Epirubicin—peripheral nervous system neoplasm	5.99e-05	0.000229	CcSEcCtD
Mesalazine—CHUK—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	5.98e-05	0.000707	CbGpPWpGaD
Mesalazine—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	5.95e-05	0.000228	CcSEcCtD
Mesalazine—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	5.95e-05	0.000227	CcSEcCtD
Mesalazine—Weight increased—Doxorubicin—peripheral nervous system neoplasm	5.94e-05	0.000227	CcSEcCtD
Mesalazine—Epistaxis—Epirubicin—peripheral nervous system neoplasm	5.93e-05	0.000227	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—CD55—peripheral nervous system neoplasm	5.92e-05	0.0007	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NCAM1—peripheral nervous system neoplasm	5.91e-05	0.000698	CbGpPWpGaD
Mesalazine—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	5.9e-05	0.000226	CcSEcCtD
Mesalazine—Sinusitis—Epirubicin—peripheral nervous system neoplasm	5.9e-05	0.000226	CcSEcCtD
Mesalazine—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	5.89e-05	0.000225	CcSEcCtD
Mesalazine—Nausea—Dactinomycin—peripheral nervous system neoplasm	5.87e-05	0.000224	CcSEcCtD
Mesalazine—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	5.87e-05	0.000224	CcSEcCtD
Mesalazine—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	5.85e-05	0.000224	CcSEcCtD
Mesalazine—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	5.85e-05	0.000224	CcSEcCtD
Mesalazine—PPARG—Developmental Biology—MET—peripheral nervous system neoplasm	5.84e-05	0.00069	CbGpPWpGaD
Mesalazine—Dizziness—Vincristine—peripheral nervous system neoplasm	5.84e-05	0.000223	CcSEcCtD
Mesalazine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	5.83e-05	0.000223	CcSEcCtD
Mesalazine—CHUK—Downstream signaling of activated FGFR—HRAS—peripheral nervous system neoplasm	5.82e-05	0.000688	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—NRAS—peripheral nervous system neoplasm	5.82e-05	0.000688	CbGpPWpGaD
Mesalazine—Infestation—Doxorubicin—peripheral nervous system neoplasm	5.82e-05	0.000222	CcSEcCtD
Mesalazine—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	5.82e-05	0.000222	CcSEcCtD
Mesalazine—Rash—Alitretinoin—peripheral nervous system neoplasm	5.78e-05	0.000221	CcSEcCtD
Mesalazine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	5.77e-05	0.000221	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	5.77e-05	0.000221	CcSEcCtD
Mesalazine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	5.75e-05	0.00022	CcSEcCtD
Mesalazine—Headache—Alitretinoin—peripheral nervous system neoplasm	5.74e-05	0.00022	CcSEcCtD
Mesalazine—CHUK—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	5.73e-05	0.000677	CbGpPWpGaD
Mesalazine—Renal failure—Doxorubicin—peripheral nervous system neoplasm	5.72e-05	0.000219	CcSEcCtD
Mesalazine—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	5.7e-05	0.000218	CcSEcCtD
Mesalazine—Urticaria—Etoposide—peripheral nervous system neoplasm	5.68e-05	0.000217	CcSEcCtD
Mesalazine—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	5.67e-05	0.000217	CcSEcCtD
Mesalazine—Jaundice—Doxorubicin—peripheral nervous system neoplasm	5.67e-05	0.000217	CcSEcCtD
Mesalazine—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	5.67e-05	0.000217	CcSEcCtD
Mesalazine—Rhinitis—Epirubicin—peripheral nervous system neoplasm	5.66e-05	0.000216	CcSEcCtD
Mesalazine—Body temperature increased—Etoposide—peripheral nervous system neoplasm	5.65e-05	0.000216	CcSEcCtD
Mesalazine—Abdominal pain—Etoposide—peripheral nervous system neoplasm	5.65e-05	0.000216	CcSEcCtD
Mesalazine—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	5.65e-05	0.000216	CcSEcCtD
Mesalazine—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	5.65e-05	0.000216	CcSEcCtD
Mesalazine—Hepatitis—Epirubicin—peripheral nervous system neoplasm	5.64e-05	0.000216	CcSEcCtD
Mesalazine—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	5.64e-05	0.000216	CcSEcCtD
Mesalazine—CHUK—Signaling by NGF—CASP3—peripheral nervous system neoplasm	5.64e-05	0.000666	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	5.63e-05	0.000665	CbGpPWpGaD
Mesalazine—Vomiting—Vincristine—peripheral nervous system neoplasm	5.61e-05	0.000215	CcSEcCtD
Mesalazine—IKBKB—Signaling Pathways—NTS—peripheral nervous system neoplasm	5.6e-05	0.000662	CbGpPWpGaD
Mesalazine—Asthenia—Cisplatin—peripheral nervous system neoplasm	5.6e-05	0.000214	CcSEcCtD
Mesalazine—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	5.6e-05	0.000214	CcSEcCtD
Mesalazine—Sweating—Doxorubicin—peripheral nervous system neoplasm	5.58e-05	0.000213	CcSEcCtD
Mesalazine—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	5.57e-05	0.000213	CcSEcCtD
Mesalazine—Rash—Vincristine—peripheral nervous system neoplasm	5.57e-05	0.000213	CcSEcCtD
Mesalazine—Dermatitis—Vincristine—peripheral nervous system neoplasm	5.56e-05	0.000213	CcSEcCtD
Mesalazine—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	5.56e-05	0.000213	CcSEcCtD
Mesalazine—Haematuria—Doxorubicin—peripheral nervous system neoplasm	5.55e-05	0.000212	CcSEcCtD
Mesalazine—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	5.55e-05	0.000212	CcSEcCtD
Mesalazine—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	5.53e-05	0.000212	CcSEcCtD
Mesalazine—Headache—Vincristine—peripheral nervous system neoplasm	5.53e-05	0.000212	CcSEcCtD
Mesalazine—PTGS1—Metabolism—GNS—peripheral nervous system neoplasm	5.51e-05	0.000652	CbGpPWpGaD
Mesalazine—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	5.5e-05	0.00021	CcSEcCtD
Mesalazine—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	5.49e-05	0.00021	CcSEcCtD
Mesalazine—CHUK—Downstream signal transduction—HRAS—peripheral nervous system neoplasm	5.47e-05	0.000647	CbGpPWpGaD
Mesalazine—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	5.46e-05	0.000209	CcSEcCtD
Mesalazine—PTGS2—C-MYB transcription factor network—HRAS—peripheral nervous system neoplasm	5.46e-05	0.000645	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR—HRAS—peripheral nervous system neoplasm	5.45e-05	0.000643	CbGpPWpGaD
Mesalazine—Nausea—Alitretinoin—peripheral nervous system neoplasm	5.44e-05	0.000208	CcSEcCtD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—AKT1—peripheral nervous system neoplasm	5.44e-05	0.000642	CbGpPWpGaD
Mesalazine—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	5.43e-05	0.000208	CcSEcCtD
Mesalazine—IKBKB—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	5.43e-05	0.000641	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—HRAS—peripheral nervous system neoplasm	5.42e-05	0.00064	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—PTPN11—peripheral nervous system neoplasm	5.4e-05	0.000639	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—HRAS—peripheral nervous system neoplasm	5.39e-05	0.000637	CbGpPWpGaD
Mesalazine—CHUK—Signaling by SCF-KIT—AKT1—peripheral nervous system neoplasm	5.37e-05	0.000635	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CD55—peripheral nervous system neoplasm	5.37e-05	0.000635	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NCAM1—peripheral nervous system neoplasm	5.35e-05	0.000633	CbGpPWpGaD
Mesalazine—CHUK—Disease—ENO2—peripheral nervous system neoplasm	5.35e-05	0.000632	CbGpPWpGaD
Mesalazine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	5.34e-05	0.000204	CcSEcCtD
Mesalazine—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	5.34e-05	0.000204	CcSEcCtD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—HRAS—peripheral nervous system neoplasm	5.31e-05	0.000628	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—MYC—peripheral nervous system neoplasm	5.29e-05	0.000625	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—NME1—peripheral nervous system neoplasm	5.29e-05	0.000625	CbGpPWpGaD
Mesalazine—CHUK—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	5.28e-05	0.000624	CbGpPWpGaD
Mesalazine—Eye disorder—Epirubicin—peripheral nervous system neoplasm	5.27e-05	0.000202	CcSEcCtD
Mesalazine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	5.27e-05	0.000202	CcSEcCtD
Mesalazine—Tinnitus—Epirubicin—peripheral nervous system neoplasm	5.26e-05	0.000201	CcSEcCtD
Mesalazine—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	5.25e-05	0.000201	CcSEcCtD
Mesalazine—Nausea—Vincristine—peripheral nervous system neoplasm	5.24e-05	0.000201	CcSEcCtD
Mesalazine—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	5.24e-05	0.0002	CcSEcCtD
Mesalazine—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	5.23e-05	0.0002	CcSEcCtD
Mesalazine—PTGS2—Disease—GNS—peripheral nervous system neoplasm	5.23e-05	0.000618	CbGpPWpGaD
Mesalazine—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	5.22e-05	0.0002	CcSEcCtD
Mesalazine—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	5.22e-05	0.0002	CcSEcCtD
Mesalazine—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	5.18e-05	0.000198	CcSEcCtD
Mesalazine—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	5.16e-05	0.000197	CcSEcCtD
Mesalazine—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	5.14e-05	0.000197	CcSEcCtD
Mesalazine—CHUK—Downstream signaling of activated FGFR—AKT1—peripheral nervous system neoplasm	5.14e-05	0.000607	CbGpPWpGaD
Mesalazine—Asthenia—Etoposide—peripheral nervous system neoplasm	5.13e-05	0.000196	CcSEcCtD
Mesalazine—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	5.13e-05	0.000196	CcSEcCtD
Mesalazine—Angiopathy—Epirubicin—peripheral nervous system neoplasm	5.12e-05	0.000196	CcSEcCtD
Mesalazine—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	5.12e-05	0.000196	CcSEcCtD
Mesalazine—IKBKB—Signaling by NGF—CASP3—peripheral nervous system neoplasm	5.11e-05	0.000604	CbGpPWpGaD
Mesalazine—PPARG—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	5.1e-05	0.000603	CbGpPWpGaD
Mesalazine—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	5.1e-05	0.000195	CcSEcCtD
Mesalazine—PTGS1—Metabolism—COX2—peripheral nervous system neoplasm	5.09e-05	0.000601	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	5.09e-05	0.000601	CbGpPWpGaD
Mesalazine—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	5.09e-05	0.000194	CcSEcCtD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	5.08e-05	0.0006	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—HRAS—peripheral nervous system neoplasm	5.07e-05	0.000599	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	5.07e-05	0.000599	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—HRAS—peripheral nervous system neoplasm	5.07e-05	0.000599	CbGpPWpGaD
Mesalazine—Chills—Epirubicin—peripheral nervous system neoplasm	5.06e-05	0.000194	CcSEcCtD
Mesalazine—Pruritus—Etoposide—peripheral nervous system neoplasm	5.06e-05	0.000194	CcSEcCtD
Mesalazine—CHUK—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	5.06e-05	0.000598	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	5.03e-05	0.000595	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—HRAS—peripheral nervous system neoplasm	5.03e-05	0.000594	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—TP53—peripheral nervous system neoplasm	5.02e-05	0.000593	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—GNAS—peripheral nervous system neoplasm	5e-05	0.00059	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	4.99e-05	0.00059	CbGpPWpGaD
Mesalazine—IKBKB—Insulin Signaling—HRAS—peripheral nervous system neoplasm	4.99e-05	0.000589	CbGpPWpGaD
Mesalazine—Alopecia—Epirubicin—peripheral nervous system neoplasm	4.99e-05	0.000191	CcSEcCtD
Mesalazine—CHUK—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	4.98e-05	0.000589	CbGpPWpGaD
Mesalazine—Vomiting—Cisplatin—peripheral nervous system neoplasm	4.96e-05	0.00019	CcSEcCtD
Mesalazine—CHUK—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	4.96e-05	0.000586	CbGpPWpGaD
Mesalazine—Mental disorder—Epirubicin—peripheral nervous system neoplasm	4.94e-05	0.000189	CcSEcCtD
Mesalazine—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	4.94e-05	0.000189	CcSEcCtD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—AKT1—peripheral nervous system neoplasm	4.93e-05	0.000582	CbGpPWpGaD
Mesalazine—Rash—Cisplatin—peripheral nervous system neoplasm	4.92e-05	0.000188	CcSEcCtD
Mesalazine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	4.92e-05	0.000188	CcSEcCtD
Mesalazine—Erythema—Epirubicin—peripheral nervous system neoplasm	4.91e-05	0.000188	CcSEcCtD
Mesalazine—ALOX5—Metabolism—ABCB1—peripheral nervous system neoplasm	4.9e-05	0.000579	CbGpPWpGaD
Mesalazine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	4.89e-05	0.000187	CcSEcCtD
Mesalazine—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	4.88e-05	0.000187	CcSEcCtD
Mesalazine—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	4.87e-05	0.000186	CcSEcCtD
Mesalazine—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	4.85e-05	0.000185	CcSEcCtD
Mesalazine—Flatulence—Epirubicin—peripheral nervous system neoplasm	4.84e-05	0.000185	CcSEcCtD
Mesalazine—CHUK—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	4.83e-05	0.000571	CbGpPWpGaD
Mesalazine—Tension—Epirubicin—peripheral nervous system neoplasm	4.82e-05	0.000184	CcSEcCtD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—HRAS—peripheral nervous system neoplasm	4.82e-05	0.000569	CbGpPWpGaD
Mesalazine—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	4.81e-05	0.000184	CcSEcCtD
Mesalazine—CHUK—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	4.81e-05	0.000568	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—NRAS—peripheral nervous system neoplasm	4.8e-05	0.000568	CbGpPWpGaD
Mesalazine—IKBKB—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	4.79e-05	0.000566	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	4.78e-05	0.000565	CbGpPWpGaD
Mesalazine—Nervousness—Epirubicin—peripheral nervous system neoplasm	4.77e-05	0.000182	CcSEcCtD
Mesalazine—PPARG—Metabolism—ENO2—peripheral nervous system neoplasm	4.77e-05	0.000564	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—AKT1—peripheral nervous system neoplasm	4.76e-05	0.000563	CbGpPWpGaD
Mesalazine—Back pain—Epirubicin—peripheral nervous system neoplasm	4.75e-05	0.000182	CcSEcCtD
Mesalazine—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	4.74e-05	0.000181	CcSEcCtD
Mesalazine—Dizziness—Etoposide—peripheral nervous system neoplasm	4.73e-05	0.000181	CcSEcCtD
Mesalazine—CHUK—Signaling by NGF—NRAS—peripheral nervous system neoplasm	4.72e-05	0.000558	CbGpPWpGaD
Mesalazine—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	4.72e-05	0.000181	CcSEcCtD
Mesalazine—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	4.72e-05	0.00018	CcSEcCtD
Mesalazine—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	4.71e-05	0.00018	CcSEcCtD
Mesalazine—CHUK—B Cell Activation—HRAS—peripheral nervous system neoplasm	4.7e-05	0.000555	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—AKT1—peripheral nervous system neoplasm	4.69e-05	0.000554	CbGpPWpGaD
Mesalazine—Chills—Doxorubicin—peripheral nervous system neoplasm	4.68e-05	0.000179	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—VIP—peripheral nervous system neoplasm	4.68e-05	0.000553	CbGpPWpGaD
Mesalazine—Nausea—Cisplatin—peripheral nervous system neoplasm	4.64e-05	0.000177	CcSEcCtD
Mesalazine—CHUK—Immune System—IFNB1—peripheral nervous system neoplasm	4.63e-05	0.000547	CbGpPWpGaD
Mesalazine—Vision blurred—Epirubicin—peripheral nervous system neoplasm	4.63e-05	0.000177	CcSEcCtD
Mesalazine—Alopecia—Doxorubicin—peripheral nervous system neoplasm	4.61e-05	0.000176	CcSEcCtD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	4.61e-05	0.000545	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	4.6e-05	0.000544	CbGpPWpGaD
Mesalazine—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	4.57e-05	0.000175	CcSEcCtD
Mesalazine—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	4.56e-05	0.000174	CcSEcCtD
Mesalazine—Vomiting—Etoposide—peripheral nervous system neoplasm	4.55e-05	0.000174	CcSEcCtD
Mesalazine—Erythema—Doxorubicin—peripheral nervous system neoplasm	4.55e-05	0.000174	CcSEcCtD
Mesalazine—Anaemia—Epirubicin—peripheral nervous system neoplasm	4.54e-05	0.000174	CcSEcCtD
Mesalazine—Rash—Etoposide—peripheral nervous system neoplasm	4.51e-05	0.000172	CcSEcCtD
Mesalazine—Dermatitis—Etoposide—peripheral nervous system neoplasm	4.51e-05	0.000172	CcSEcCtD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	4.49e-05	0.000531	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—PTPN11—peripheral nervous system neoplasm	4.48e-05	0.000529	CbGpPWpGaD
Mesalazine—Headache—Etoposide—peripheral nervous system neoplasm	4.48e-05	0.000171	CcSEcCtD
Mesalazine—CHUK—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	4.48e-05	0.000529	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	4.48e-05	0.000529	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—AKT1—peripheral nervous system neoplasm	4.48e-05	0.000529	CbGpPWpGaD
Mesalazine—Flatulence—Doxorubicin—peripheral nervous system neoplasm	4.48e-05	0.000171	CcSEcCtD
Mesalazine—Tension—Doxorubicin—peripheral nervous system neoplasm	4.46e-05	0.000171	CcSEcCtD
Mesalazine—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	4.45e-05	0.00017	CcSEcCtD
Mesalazine—CHUK—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	4.44e-05	0.000525	CbGpPWpGaD
Mesalazine—Malaise—Epirubicin—peripheral nervous system neoplasm	4.43e-05	0.000169	CcSEcCtD
Mesalazine—Nervousness—Doxorubicin—peripheral nervous system neoplasm	4.41e-05	0.000169	CcSEcCtD
Mesalazine—Vertigo—Epirubicin—peripheral nervous system neoplasm	4.41e-05	0.000169	CcSEcCtD
Mesalazine—Syncope—Epirubicin—peripheral nervous system neoplasm	4.41e-05	0.000168	CcSEcCtD
Mesalazine—IKBKB—Insulin Signaling—AKT1—peripheral nervous system neoplasm	4.4e-05	0.00052	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	4.4e-05	0.00052	CbGpPWpGaD
Mesalazine—Leukopenia—Epirubicin—peripheral nervous system neoplasm	4.4e-05	0.000168	CcSEcCtD
Mesalazine—Back pain—Doxorubicin—peripheral nervous system neoplasm	4.4e-05	0.000168	CcSEcCtD
Mesalazine—CHUK—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	4.38e-05	0.000518	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GNS—peripheral nervous system neoplasm	4.38e-05	0.000517	CbGpPWpGaD
Mesalazine—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	4.37e-05	0.000167	CcSEcCtD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—NRAS—peripheral nervous system neoplasm	4.36e-05	0.000515	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TP53—peripheral nervous system neoplasm	4.35e-05	0.000514	CbGpPWpGaD
Mesalazine—Palpitations—Epirubicin—peripheral nervous system neoplasm	4.34e-05	0.000166	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	4.32e-05	0.000511	CbGpPWpGaD
Mesalazine—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	4.32e-05	0.000165	CcSEcCtD
Mesalazine—CHUK—Disease—SLC2A1—peripheral nervous system neoplasm	4.31e-05	0.000509	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	4.3e-05	0.000508	CbGpPWpGaD
Mesalazine—Cough—Epirubicin—peripheral nervous system neoplasm	4.29e-05	0.000164	CcSEcCtD
Mesalazine—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	4.28e-05	0.000164	CcSEcCtD
Mesalazine—IKBKB—Signaling by NGF—NRAS—peripheral nervous system neoplasm	4.28e-05	0.000506	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—ERBB2—peripheral nervous system neoplasm	4.27e-05	0.000505	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—HRAS—peripheral nervous system neoplasm	4.26e-05	0.000503	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—AKT1—peripheral nervous system neoplasm	4.26e-05	0.000503	CbGpPWpGaD
Mesalazine—Nausea—Etoposide—peripheral nervous system neoplasm	4.25e-05	0.000162	CcSEcCtD
Mesalazine—IKBKB—Signaling Pathways—VIP—peripheral nervous system neoplasm	4.25e-05	0.000502	CbGpPWpGaD
Mesalazine—Hypertension—Epirubicin—peripheral nervous system neoplasm	4.24e-05	0.000162	CcSEcCtD
Mesalazine—IKBKB—MAPK Signaling Pathway—AKT1—peripheral nervous system neoplasm	4.24e-05	0.0005	CbGpPWpGaD
Mesalazine—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	4.22e-05	0.000161	CcSEcCtD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	4.21e-05	0.000498	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IFNB1—peripheral nervous system neoplasm	4.2e-05	0.000496	CbGpPWpGaD
Mesalazine—Anaemia—Doxorubicin—peripheral nervous system neoplasm	4.2e-05	0.000161	CcSEcCtD
Mesalazine—PTGS2—Metabolism—NME1—peripheral nervous system neoplasm	4.2e-05	0.000496	CbGpPWpGaD
Mesalazine—Myalgia—Epirubicin—peripheral nervous system neoplasm	4.18e-05	0.00016	CcSEcCtD
Mesalazine—Chest pain—Epirubicin—peripheral nervous system neoplasm	4.18e-05	0.00016	CcSEcCtD
Mesalazine—Arthralgia—Epirubicin—peripheral nervous system neoplasm	4.18e-05	0.00016	CcSEcCtD
Mesalazine—Anxiety—Epirubicin—peripheral nervous system neoplasm	4.17e-05	0.000159	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	4.15e-05	0.000159	CcSEcCtD
Mesalazine—CHUK—B Cell Activation—AKT1—peripheral nervous system neoplasm	4.15e-05	0.00049	CbGpPWpGaD
Mesalazine—Discomfort—Epirubicin—peripheral nervous system neoplasm	4.13e-05	0.000158	CcSEcCtD
Mesalazine—Malaise—Doxorubicin—peripheral nervous system neoplasm	4.1e-05	0.000157	CcSEcCtD
Mesalazine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	4.09e-05	0.000156	CcSEcCtD
Mesalazine—Vertigo—Doxorubicin—peripheral nervous system neoplasm	4.08e-05	0.000156	CcSEcCtD
Mesalazine—Syncope—Doxorubicin—peripheral nervous system neoplasm	4.08e-05	0.000156	CcSEcCtD
Mesalazine—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	4.07e-05	0.000156	CcSEcCtD
Mesalazine—IKBKB—Innate Immune System—PTPN11—peripheral nervous system neoplasm	4.06e-05	0.00048	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	4.06e-05	0.00048	CbGpPWpGaD
Mesalazine—Confusional state—Epirubicin—peripheral nervous system neoplasm	4.04e-05	0.000155	CcSEcCtD
Mesalazine—PTGS2—Metabolism—COX2—peripheral nervous system neoplasm	4.04e-05	0.000477	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—BCHE—peripheral nervous system neoplasm	4.03e-05	0.000476	CbGpPWpGaD
Mesalazine—Palpitations—Doxorubicin—peripheral nervous system neoplasm	4.02e-05	0.000154	CcSEcCtD
Mesalazine—Oedema—Epirubicin—peripheral nervous system neoplasm	4.01e-05	0.000153	CcSEcCtD
Mesalazine—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	4.01e-05	0.000153	CcSEcCtD
Mesalazine—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	3.99e-05	0.000153	CcSEcCtD
Mesalazine—Infection—Epirubicin—peripheral nervous system neoplasm	3.98e-05	0.000152	CcSEcCtD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	3.97e-05	0.000469	CbGpPWpGaD
Mesalazine—Cough—Doxorubicin—peripheral nervous system neoplasm	3.97e-05	0.000152	CcSEcCtD
Mesalazine—Shock—Epirubicin—peripheral nervous system neoplasm	3.94e-05	0.000151	CcSEcCtD
Mesalazine—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	3.93e-05	0.00015	CcSEcCtD
Mesalazine—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	3.93e-05	0.00015	CcSEcCtD
Mesalazine—Hypertension—Doxorubicin—peripheral nervous system neoplasm	3.92e-05	0.00015	CcSEcCtD
Mesalazine—IKBKB—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	3.92e-05	0.000463	CbGpPWpGaD
Mesalazine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	3.91e-05	0.00015	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	3.9e-05	0.000461	CbGpPWpGaD
Mesalazine—Skin disorder—Epirubicin—peripheral nervous system neoplasm	3.89e-05	0.000149	CcSEcCtD
Mesalazine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	3.88e-05	0.000148	CcSEcCtD
Mesalazine—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	3.87e-05	0.000148	CcSEcCtD
Mesalazine—Myalgia—Doxorubicin—peripheral nervous system neoplasm	3.87e-05	0.000148	CcSEcCtD
Mesalazine—Chest pain—Doxorubicin—peripheral nervous system neoplasm	3.87e-05	0.000148	CcSEcCtD
Mesalazine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	3.86e-05	0.000147	CcSEcCtD
Mesalazine—PPARG—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.84e-05	0.000454	CbGpPWpGaD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	3.84e-05	0.000147	CcSEcCtD
Mesalazine—Discomfort—Doxorubicin—peripheral nervous system neoplasm	3.82e-05	0.000146	CcSEcCtD
Mesalazine—Anorexia—Epirubicin—peripheral nervous system neoplasm	3.82e-05	0.000146	CcSEcCtD
Mesalazine—PPARG—Metabolism—TH—peripheral nervous system neoplasm	3.79e-05	0.000448	CbGpPWpGaD
Mesalazine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	3.78e-05	0.000145	CcSEcCtD
Mesalazine—IKBKB—B Cell Activation—AKT1—peripheral nervous system neoplasm	3.76e-05	0.000444	CbGpPWpGaD
Mesalazine—Hypotension—Epirubicin—peripheral nervous system neoplasm	3.75e-05	0.000143	CcSEcCtD
Mesalazine—Confusional state—Doxorubicin—peripheral nervous system neoplasm	3.74e-05	0.000143	CcSEcCtD
Mesalazine—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	3.71e-05	0.000142	CcSEcCtD
Mesalazine—Oedema—Doxorubicin—peripheral nervous system neoplasm	3.71e-05	0.000142	CcSEcCtD
Mesalazine—Infection—Doxorubicin—peripheral nervous system neoplasm	3.69e-05	0.000141	CcSEcCtD
Mesalazine—PTGS2—Disease—PPP3R1—peripheral nervous system neoplasm	3.66e-05	0.000432	CbGpPWpGaD
Mesalazine—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	3.65e-05	0.00014	CcSEcCtD
Mesalazine—Shock—Doxorubicin—peripheral nervous system neoplasm	3.65e-05	0.00014	CcSEcCtD
Mesalazine—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	3.64e-05	0.000139	CcSEcCtD
Mesalazine—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	3.63e-05	0.000139	CcSEcCtD
Mesalazine—Insomnia—Epirubicin—peripheral nervous system neoplasm	3.63e-05	0.000139	CcSEcCtD
Mesalazine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	3.62e-05	0.000138	CcSEcCtD
Mesalazine—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	3.6e-05	0.000138	CcSEcCtD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	3.6e-05	0.000425	CbGpPWpGaD
Mesalazine—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	3.6e-05	0.000138	CcSEcCtD
Mesalazine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	3.59e-05	0.000137	CcSEcCtD
Mesalazine—CHUK—Immune System—HGF—peripheral nervous system neoplasm	3.58e-05	0.000423	CbGpPWpGaD
Mesalazine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	3.57e-05	0.000137	CcSEcCtD
Mesalazine—Somnolence—Epirubicin—peripheral nervous system neoplasm	3.56e-05	0.000136	CcSEcCtD
Mesalazine—CHUK—Innate Immune System—ERBB2—peripheral nervous system neoplasm	3.54e-05	0.000418	CbGpPWpGaD
Mesalazine—Anorexia—Doxorubicin—peripheral nervous system neoplasm	3.54e-05	0.000135	CcSEcCtD
Mesalazine—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	3.53e-05	0.000135	CcSEcCtD
Mesalazine—CHUK—Cytokine Signaling in Immune system—HRAS—peripheral nervous system neoplasm	3.52e-05	0.000415	CbGpPWpGaD
Mesalazine—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	3.49e-05	0.000133	CcSEcCtD
Mesalazine—Hypotension—Doxorubicin—peripheral nervous system neoplasm	3.47e-05	0.000133	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	3.46e-05	0.000132	CcSEcCtD
Mesalazine—Fatigue—Epirubicin—peripheral nervous system neoplasm	3.46e-05	0.000132	CcSEcCtD
Mesalazine—CHUK—Signaling by NGF—HRAS—peripheral nervous system neoplasm	3.46e-05	0.000408	CbGpPWpGaD
Mesalazine—Pain—Epirubicin—peripheral nervous system neoplasm	3.43e-05	0.000131	CcSEcCtD
Mesalazine—Constipation—Epirubicin—peripheral nervous system neoplasm	3.43e-05	0.000131	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	3.4e-05	0.000402	CbGpPWpGaD
Mesalazine—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	3.38e-05	0.000129	CcSEcCtD
Mesalazine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	3.36e-05	0.000128	CcSEcCtD
Mesalazine—PTGS1—Metabolism—ENO2—peripheral nervous system neoplasm	3.34e-05	0.000395	CbGpPWpGaD
Mesalazine—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	3.33e-05	0.000127	CcSEcCtD
Mesalazine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	3.31e-05	0.000126	CcSEcCtD
Mesalazine—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	3.3e-05	0.000126	CcSEcCtD
Mesalazine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	3.3e-05	0.000126	CcSEcCtD
Mesalazine—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	3.28e-05	0.000125	CcSEcCtD
Mesalazine—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	3.27e-05	0.000125	CcSEcCtD
Mesalazine—PPARG—Developmental Biology—NRAS—peripheral nervous system neoplasm	3.25e-05	0.000384	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.25e-05	0.000384	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HGF—peripheral nervous system neoplasm	3.24e-05	0.000383	CbGpPWpGaD
Mesalazine—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	3.22e-05	0.000123	CcSEcCtD
Mesalazine—PPARG—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	3.22e-05	0.00038	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—ERBB2—peripheral nervous system neoplasm	3.21e-05	0.000379	CbGpPWpGaD
Mesalazine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	3.2e-05	0.000122	CcSEcCtD
Mesalazine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	3.2e-05	0.000122	CcSEcCtD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—HRAS—peripheral nervous system neoplasm	3.19e-05	0.000377	CbGpPWpGaD
Mesalazine—Urticaria—Epirubicin—peripheral nervous system neoplasm	3.18e-05	0.000122	CcSEcCtD
Mesalazine—Constipation—Doxorubicin—peripheral nervous system neoplasm	3.17e-05	0.000121	CcSEcCtD
Mesalazine—Pain—Doxorubicin—peripheral nervous system neoplasm	3.17e-05	0.000121	CcSEcCtD
Mesalazine—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	3.17e-05	0.000121	CcSEcCtD
Mesalazine—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	3.17e-05	0.000121	CcSEcCtD
Mesalazine—PTGS2—Disease—ENO2—peripheral nervous system neoplasm	3.17e-05	0.000374	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—HRAS—peripheral nervous system neoplasm	3.13e-05	0.00037	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GNAS—peripheral nervous system neoplasm	3.09e-05	0.000365	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	3.08e-05	0.000364	CbGpPWpGaD
Mesalazine—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	3.06e-05	0.000117	CcSEcCtD
Mesalazine—CHUK—Signaling by NGF—AKT1—peripheral nervous system neoplasm	3.05e-05	0.000361	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ABCB1—peripheral nervous system neoplasm	3.04e-05	0.000359	CbGpPWpGaD
Mesalazine—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	3.03e-05	0.000116	CcSEcCtD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	2.96e-05	0.000349	CbGpPWpGaD
Mesalazine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	2.95e-05	0.000113	CcSEcCtD
Mesalazine—Urticaria—Doxorubicin—peripheral nervous system neoplasm	2.95e-05	0.000113	CcSEcCtD
Mesalazine—IKBKB—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.94e-05	0.000348	CbGpPWpGaD
Mesalazine—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	2.93e-05	0.000112	CcSEcCtD
Mesalazine—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	2.93e-05	0.000112	CcSEcCtD
Mesalazine—Asthenia—Epirubicin—peripheral nervous system neoplasm	2.88e-05	0.00011	CcSEcCtD
Mesalazine—Pruritus—Epirubicin—peripheral nervous system neoplasm	2.84e-05	0.000108	CcSEcCtD
Mesalazine—PTGS1—Metabolism—BCHE—peripheral nervous system neoplasm	2.82e-05	0.000334	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.78e-05	0.000328	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—AKT1—peripheral nervous system neoplasm	2.77e-05	0.000327	CbGpPWpGaD
Mesalazine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	2.74e-05	0.000105	CcSEcCtD
Mesalazine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	2.73e-05	0.000105	CcSEcCtD
Mesalazine—CHUK—Innate Immune System—NRAS—peripheral nervous system neoplasm	2.69e-05	0.000318	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.69e-05	0.000318	CbGpPWpGaD
Mesalazine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	2.66e-05	0.000102	CcSEcCtD
Mesalazine—PTGS1—Metabolism—TH—peripheral nervous system neoplasm	2.65e-05	0.000314	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ENO2—peripheral nervous system neoplasm	2.65e-05	0.000313	CbGpPWpGaD
Mesalazine—Dizziness—Epirubicin—peripheral nervous system neoplasm	2.65e-05	0.000101	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.65e-05	0.000313	CbGpPWpGaD
Mesalazine—Pruritus—Doxorubicin—peripheral nervous system neoplasm	2.62e-05	0.0001	CcSEcCtD
Mesalazine—CHUK—Immune System—PTPN11—peripheral nervous system neoplasm	2.61e-05	0.000308	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	2.59e-05	0.000306	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SLC2A1—peripheral nervous system neoplasm	2.55e-05	0.000302	CbGpPWpGaD
Mesalazine—Vomiting—Epirubicin—peripheral nervous system neoplasm	2.55e-05	9.75e-05	CcSEcCtD
Mesalazine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	2.54e-05	9.71e-05	CcSEcCtD
Mesalazine—Rash—Epirubicin—peripheral nervous system neoplasm	2.53e-05	9.67e-05	CcSEcCtD
Mesalazine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	2.53e-05	9.66e-05	CcSEcCtD
Mesalazine—IKBKB—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.52e-05	0.000297	CbGpPWpGaD
Mesalazine—Headache—Epirubicin—peripheral nervous system neoplasm	2.51e-05	9.6e-05	CcSEcCtD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	2.5e-05	0.000295	CbGpPWpGaD
Mesalazine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	2.45e-05	9.38e-05	CcSEcCtD
Mesalazine—IKBKB—Innate Immune System—NRAS—peripheral nervous system neoplasm	2.44e-05	0.000289	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.43e-05	0.000287	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTPN11—peripheral nervous system neoplasm	2.41e-05	0.000285	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.4e-05	0.000284	CbGpPWpGaD
Mesalazine—Nausea—Epirubicin—peripheral nervous system neoplasm	2.38e-05	9.11e-05	CcSEcCtD
Mesalazine—PPARG—Developmental Biology—HRAS—peripheral nervous system neoplasm	2.38e-05	0.000281	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PTPN11—peripheral nervous system neoplasm	2.37e-05	0.00028	CbGpPWpGaD
Mesalazine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	2.36e-05	9.02e-05	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	2.35e-05	0.000277	CbGpPWpGaD
Mesalazine—Rash—Doxorubicin—peripheral nervous system neoplasm	2.34e-05	8.94e-05	CcSEcCtD
Mesalazine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	2.34e-05	8.94e-05	CcSEcCtD
Mesalazine—Headache—Doxorubicin—peripheral nervous system neoplasm	2.32e-05	8.89e-05	CcSEcCtD
Mesalazine—PTGS2—Metabolism—BCHE—peripheral nervous system neoplasm	2.24e-05	0.000265	CbGpPWpGaD
Mesalazine—Nausea—Doxorubicin—peripheral nervous system neoplasm	2.2e-05	8.43e-05	CcSEcCtD
Mesalazine—IKBKB—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.2e-05	0.00026	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GNAS—peripheral nervous system neoplasm	2.17e-05	0.000256	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.14e-05	0.000253	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ABCB1—peripheral nervous system neoplasm	2.13e-05	0.000251	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TH—peripheral nervous system neoplasm	2.11e-05	0.000249	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.1e-05	0.000248	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ERBB2—peripheral nervous system neoplasm	2.06e-05	0.000244	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.97e-05	0.000233	CbGpPWpGaD
Mesalazine—CHUK—Disease—ERBB2—peripheral nervous system neoplasm	1.9e-05	0.000225	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.89e-05	0.000224	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ERBB2—peripheral nervous system neoplasm	1.87e-05	0.000221	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.79e-05	0.000211	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.74e-05	0.000206	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GNAS—peripheral nervous system neoplasm	1.72e-05	0.000203	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.72e-05	0.000203	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.69e-05	0.000199	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.69e-05	0.000199	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.67e-05	0.000197	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.58e-05	0.000186	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NRAS—peripheral nervous system neoplasm	1.57e-05	0.000185	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—peripheral nervous system neoplasm	1.55e-05	0.000183	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.53e-05	0.000181	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.52e-05	0.000179	CbGpPWpGaD
Mesalazine—CHUK—Disease—NRAS—peripheral nervous system neoplasm	1.45e-05	0.000171	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PTPN11—peripheral nervous system neoplasm	1.43e-05	0.000169	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NRAS—peripheral nervous system neoplasm	1.42e-05	0.000168	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—peripheral nervous system neoplasm	1.35e-05	0.000159	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—AKT1—peripheral nervous system neoplasm	1.35e-05	0.000159	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.33e-05	0.000158	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.21e-05	0.000143	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.21e-05	0.000143	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HRAS—peripheral nervous system neoplasm	1.15e-05	0.000136	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERBB2—peripheral nervous system neoplasm	1.13e-05	0.000133	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.1e-05	0.00013	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—AKT1—peripheral nervous system neoplasm	1.07e-05	0.000127	CbGpPWpGaD
Mesalazine—CHUK—Disease—HRAS—peripheral nervous system neoplasm	1.06e-05	0.000125	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HRAS—peripheral nervous system neoplasm	1.04e-05	0.000123	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.01e-05	0.00012	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT1—peripheral nervous system neoplasm	1.01e-05	0.00012	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.45e-06	0.000112	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT1—peripheral nervous system neoplasm	9.36e-06	0.000111	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NRAS—peripheral nervous system neoplasm	9.2e-06	0.000109	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT1—peripheral nervous system neoplasm	9.19e-06	0.000109	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NRAS—peripheral nervous system neoplasm	8.58e-06	0.000101	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—peripheral nervous system neoplasm	8.57e-06	0.000101	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AKT1—peripheral nervous system neoplasm	8.35e-06	9.86e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—peripheral nervous system neoplasm	7.99e-06	9.45e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.76e-06	9.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.42e-06	8.77e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.04e-06	8.32e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.73e-06	7.95e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.55e-06	7.74e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HRAS—peripheral nervous system neoplasm	6.28e-06	7.42e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.94e-06	7.02e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKT1—peripheral nervous system neoplasm	5.85e-06	6.91e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT1—peripheral nervous system neoplasm	5.54e-06	6.55e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKT1—peripheral nervous system neoplasm	4.64e-06	5.49e-05	CbGpPWpGaD
